Back to Search
Start Over
Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: results of a Japanese nationwide survey.
- Source :
-
Annals of nuclear medicine [Ann Nucl Med] 2011 Nov; Vol. 25 (9), pp. 657-66. Date of Electronic Publication: 2011 Jul 01. - Publication Year :
- 2011
-
Abstract
- Objective: The aim of this study was to estimate radiation exposure and evaluate the risks and benefits of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in cancer screening.<br />Methods: A nationwide survey of FDG-PET cancer screening was conducted in 2006, and the results were analyzed with a common index, "extension/shortening of the average life expectancy."<br />Results: The average estimated effective dose was 4.4 mSv (male 4.7 mSv; female 4.0 mSv) for dedicated PET and 13.5 mSv (male 14.2 mSv; female 12.8 mSv) for PET/computed tomography (CT). The risk-benefit break-even age from the viewpoint of radiation exposure was in the 40s for men and 30s for women for dedicated PET and in the 50s for men and 50s (variable injection dose) or 60s (constant injection dose) for women for PET/CT.<br />Conclusions: FDG-PET cancer screening is beneficial for examinees above the break-even ages. The risks and benefits should be explained to examinees because of the larger radiation used in cancer FDG-PET screening compared with other X-ray tests.
- Subjects :
- Adult
Aged
Aged, 80 and over
Female
Humans
Japan
Life Expectancy
Male
Middle Aged
Radiation Dosage
Risk Assessment
Young Adult
Data Collection
Early Detection of Cancer adverse effects
Environmental Exposure adverse effects
Environmental Exposure analysis
Fluorodeoxyglucose F18 adverse effects
Neoplasms diagnostic imaging
Positron-Emission Tomography adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1864-6433
- Volume :
- 25
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Annals of nuclear medicine
- Publication Type :
- Academic Journal
- Accession number :
- 21720777
- Full Text :
- https://doi.org/10.1007/s12149-011-0511-1